- Home
- SKBL vs KYTX Comparison
SKBL vs KYTX Comparison
Compare SKBL & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKBL
- KYTX
- Stock Information
- Founded
- SKBL 2012
- KYTX 2018
- Country
- SKBL Hong Kong
- KYTX United States
- Employees
- SKBL N/A
- KYTX N/A
- Industry
- SKBL
- KYTX
- Sector
- SKBL
- KYTX
- Exchange
- SKBL NYSE
- KYTX NYSE
- Market Cap
- SKBL 389.6M
- KYTX 92.1M
- IPO Year
- SKBL 2025
- KYTX 2024
- Fundamental
- Price
- SKBL $12.28
- KYTX $2.13
- Analyst Decision
- SKBL
- KYTX Buy
- Analyst Count
- SKBL 0
- KYTX 5
- Target Price
- SKBL N/A
- KYTX $18.80
- AVG Volume (30 Days)
- SKBL 742.6K
- KYTX 205.4K
- Earning Date
- SKBL 01-01-0001
- KYTX 05-16-2025
- Dividend Yield
- SKBL N/A
- KYTX N/A
- EPS Growth
- SKBL N/A
- KYTX N/A
- EPS
- SKBL 0.03
- KYTX N/A
- Revenue
- SKBL $49,638,709.00
- KYTX N/A
- Revenue This Year
- SKBL N/A
- KYTX N/A
- Revenue Next Year
- SKBL N/A
- KYTX N/A
- P/E Ratio
- SKBL $385.51
- KYTX N/A
- Revenue Growth
- SKBL 9.58
- KYTX N/A
- 52 Week Low
- SKBL $6.93
- KYTX $1.78
- 52 Week High
- SKBL $13.50
- KYTX $17.55
- Technical
- Relative Strength Index (RSI)
- SKBL N/A
- KYTX 49.61
- Support Level
- SKBL N/A
- KYTX $1.92
- Resistance Level
- SKBL N/A
- KYTX $2.38
- Average True Range (ATR)
- SKBL 0.00
- KYTX 0.18
- MACD
- SKBL 0.00
- KYTX 0.02
- Stochastic Oscillator
- SKBL 0.00
- KYTX 55.36
About SKBL SKYLINE BUILDERS GROUP HOLDING LIMI
Skyline Builders Group Holding Ltd is an holding company operates through its subsidiary. It is a Public Works Contractor company undertaking roads and drainage in Hong Kong. Its construction activities mainly include public civil engineering works, such as road and drainage works, in Hong Kong.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.